Skip to main content

Eloctate FDA Approval History

FDA Approved: Yes (First approved June 6, 2014)
Brand name: Eloctate
Generic name: antihemophilic factor (recombinant)
Dosage form: for Injection
Company: Biogen
Treatment for: Hemophilia A

Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.

Development timeline for Eloctate

Jun  6, 2014Approval FDA Approves Eloctate - first Antihemophilic Factor, Fc Fusion Protein for Patients with Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.